Taiwan Biomaterial Valuation

Q: What is the Fair Price of 6649 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6649 (NT$35.2) is trading above our estimate of [[fair value]] (NT$2.69)

Is 6649 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6649 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6649 (NT$35.2) is trading above our estimate of fair value (NT$2.69)

Significantly Below Fair Value: 6649 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6649?

Key metric: As 6649 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6649. This is calculated by dividing 6649's market cap by their current revenue.
What is 6649's PS Ratio?
PS Ratio	17.7x
Sales	NT$83.74m
Market Cap	NT$1.48b

6649 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.8x
Enterprise Value/EBITDA	-270.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6649's PS Ratio compare to its peers?

The above table shows the PS ratio for 6649 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
6543 Perfect Medical Industry	1.8x	n/a	NT$1.4b
4150 Unicon Optical	2.3x	n/a	NT$2.1b
1813 Polylite Taiwan	2.8x	n/a	NT$909.4m
6747 Brighten Optix	5x	n/a	NT$3.7b
6649 Taiwan Biomaterial	17.7x	n/a	NT$1.5b

Price-To-Sales vs Peers: 6649 is expensive based on its Price-To-Sales Ratio (17.7x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does 6649's PS Ratio compare vs other companies in the TW Medical Equipment Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
4116 BenQ Medical Technology	0.5x	n/a	US$65.32m
4121 Rossmax International	0.4x	n/a	US$45.23m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6649 is expensive based on its Price-To-Sales Ratio (17.7x) compared to the TW Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is 6649's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6649 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	17.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6649's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Universal Vision Biotechnology

NT$18.3b

Operates a chain of eye care clinics in Taiwan and China.

3218

NT$215.50

1.9%

-27.1%

Hi-Clearance

NT$6.2b

Supplies medical devices for the renal, cardiac, radiation, dental, oral surgery, and metabolism markets in Taiwan.

1788

NT$138.50

0.4%

2.6%

Pacific Hospital Supply

NT$6.5b

Manufactures, processes, and sells medical disposable products and equipment in Taiwan.

4126

NT$89.00

-0.3%

6.0%